EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia

Thomas Bauch iD, Georg Hempel iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19410 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Thomas Bauch und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Institute for Pharmaceutical and Medical Chemistry, University of Münster, Münster, Germany. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Asparaginase, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Physiologically based pharmacokinetic (PBPK) modelling is an alternative modelling technique that is increasingly used in pharmacokinetics. Due to its nature, it can be complementarily employed to population pharmacokinetics, especially when it comes to small population size. Here, we report the proof of concept of its application to accurately describe the pharmacokinetics of a recombinant L‐asparaginase in paediatric patients with acute lymphoblastic leukaemia. Data from two randomized, double‐blind, phase II/III clinical studies (MC‐ASP.4/ALL; MC‐ASP.5/ALL) were included to setup and evaluate the final model, respectively. Final population values for basic pharmacokinetic parameters were calculated (clearance: 0.0569 L/h/19.5 kg, volume of distribution: 1.251 L, half‐life: 18.5 h, trough concentration: 140.9 IU/L). Pharmacokinetic parameter prediction as well as predictive performance of the model proofed to be comparable to a separately developed population pharmacokinetic model with 13% deviation in predicted median L‐asparaginase trough levels. To the best of our knowledge, this is the first whole‐body PBPK model of a non‐antibody therapeutic protein.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaAsparaginaseModels, BiologicalHumansChildChild, PreschoolFemaleMaleAdolescentProof of Concept StudyDouble-Blind MethodAntineoplastic AgentsInfant

Stichwörter der Autor:innen

L‐asparaginaseacute leukaemiamathematical modellingpaediatric haematologypharmacokinetics

Substanzen

AsparaginaseAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Institute for Pharmaceutical and Medical Chemistry, University of Münster, Münster, Germany.

ORCID-Profile: Thomas Bauch, Georg Hempel

Zitieren

APA

Bauch, T., & Hempel, G. (2024). Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.19410

Vancouver

Bauch T, Hempel G. Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia. British Journal of Haematology. 2024. doi:10.1111/bjh.19410

BibTeX
@article{Bauch2024,
  author = {Bauch, Thomas and Hempel, Georg},
  title = {Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19410}
}
Kostenlos starten →